Application
The specific inhibitor of Smad3 (SIS3) has been used to block transforming growth factor (TGF)-β/ mothers against decapentaplegic homolog 3 (SMAD3) signaling to characterize the signaling pathways that contribute to the activation of signal transducer and activator of transcription 3 (STAT3) in lung fibroblasts. It has also been used as a SMAD3 inhibitor in serum-free media to assess its ability to prevent the acrolein effect in ARPE-19 cells.
Biochem/physiol Actions
The specific inhibitor of Smad3 (SIS3) is a pyrrolopyridine compound. It selectively blocks transforming growth factor (TGF)-β1-dependent mothers against decapentaplegic homolog 3 (Smad3) phosphorylation and Smad3-mediated cellular pathway without affecting Smad2, p38 mitogen-activated protein kinase (MAPK), extracellular-signal-regulated kinase (ERK), or phosphoinositide 3-kinase (PI3K) signaling. Through its inhibitory function, SIS3 regulates fibrosis, apoptosis, and inflammation in mouse unilateral ureteral obstruction (UUO) kidneys. Therefore, SIS3 can be an effective drug in further anti-fibrosis treatment of kidney disease.
Primary TargetTGF-β1-dependent Smad3 phosphorylation and Smad3-mediated cellular signaling
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Reversible: noProduct does not compete with ATP.Cell permeable: yesJinnin, M., et al. 2006. Mol. Pharmacol.69, 597.
Packaging
1 mg in Plastic ampoule
Packaged under inert gas
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Warning
Toxicity: Irritant (B)
This product has met the following criteria to qualify for the following awards: